Walrinvax™ Pre-Qualified by WHO
(August 5th 2024, Kunming) Walvax Biotechnology Co., Ltd. ("Walvax", stock code: 300142.SZ) is pleased to announce that the World Health Organization has accepted pre-qualification for Walrinvax™, a prophylactic pichia pastoris-expressed bivalent (types 16 and 18) HPV vaccine developed by Shanghai Zerun Biotechnology Co., Ltd. (ZerunBio), a subsidiary of Walvax.
This certification indicates that the vaccine's safety, efficacy, and quality control meet WHO standards and that the production management system of our facility complies with WHO Good Manufacturing Practices (GMP) requirements.
According to WHO’s Global Strategy to Accelerate the Elimination of Cervical Cancer, it is estimated that the annual global demand for routine HPV vaccinations will reach 100 million doses by 2024, then stable at 120 million doses per year. There is currently a significant supply demand gap worldwide, and we believe our HPV-2 will be of great help to fill the gap with pre-qualification.
At current, the maximum production capacity of our HPV-2 reaches 20 million doses. At the 2020 Global Vaccine Summit, Mr. Yunchun Li, Chairman of Walvax, committed to supplying more than half of our capacity to the global market.